Treatment of pulmonary tuberculosis

作者: J van Loenhout-Rooyackers

DOI: 10.1016/S0300-2977(98)00067-9

关键词:

摘要: Recently the duration of treatment for pulmonary tuberculosis in The Netherlands was shortened from nine to six months. A months regimen containing isoniazid (H), rifampicin (R) and pyrazinamid (Z) daily two months, followed by H R another four (2HRZ/2HR) has been proven effective tuberculosis, provided cause is a fully susceptible strain M. tuberculosis. Worldwide there an increase drug-resistant Since at start susceptibility tests often are not available, fourth drug must be added intensive phase. Ethambutol preferred. This means that one always starts with 4 drugs unless patient contact index-case sure he will compliant or infected past before 1940, received never tuberculostatic no exogenous reinfection. If treated previously anti-tuberculosis resistance likely, regimens should contain least which before, while fifth routinely Amikacin preferred, since cross-resistance streptomycin. Consensus on extra-pulmonary yet reached, but basically principles same. also true HIV patients. In some serious clinical situations (meningitis, miliary, spine tb) still 9-12 Early involvement public health nurse municipal department (GGD) necessary ensure compliance supervision.

参考文章(11)
A. J. Crowle, J. A. Sbarbaro, F. N. Judson, Mary H. May, The effect of ethambutol on tubercle bacilli within cultured human macrophages. The American review of respiratory disease. ,vol. 132, pp. 742- 745 ,(1985) , 10.1164/ARRD.1985.132.4.742
Alfred J. Crowle, J. A. Sbarbaro, Mary H. May, Inhibition by pyrazinamide of tubercle bacilli within cultured human macrophages. The American review of respiratory disease. ,vol. 134, pp. 1052- 1055 ,(1986) , 10.1164/ARRD.1986.134.5.1052
J B Bass, L S Farer, P C Hopewell, R O'Brien, R F Jacobs, F Ruben, D E Snider, G Thornton, Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention. American Journal of Respiratory and Critical Care Medicine. ,vol. 149, pp. 1359- 1374 ,(1994) , 10.1164/AJRCCM.149.5.8173779
K. Takayama, E. L. Armstrong, K. A. Kunugi, J. O. Kilburn, Inhibition by Ethambutol of Mycolic Acid Transfer into the Cell Wall of Mycobacterium smegmatis Antimicrobial Agents and Chemotherapy. ,vol. 16, pp. 240- 242 ,(1979) , 10.1128/AAC.16.2.240
RICHARD D. O'TOOLE, Dexamethasone in Tuberculous Meningitis Annals of Internal Medicine. ,vol. 70, pp. 39- 48 ,(1969) , 10.7326/0003-4819-70-1-39
Wallace Fox, Whither short-course chemotherapy? British Journal of Diseases of The Chest. ,vol. 75, pp. 331- 357 ,(1981) , 10.1016/0007-0971(81)90022-X
J.I.G. Strang, D.G. Gibson, A.J. Nunn, H.H.S. Kakaza, D.J. Girling, W. Fox, CONTROLLED TRIAL OF PREDNISOLONE AS ADJUVANT IN TREATMENT OF TUBERCULOUS CONSTRICTIVE PERICARDITIS IN TRANSKEI The Lancet. ,vol. 330, pp. 1418- 1422 ,(1987) , 10.1016/S0140-6736(87)91127-5
J. Veen, A.L.M. Verbeek, J.H. van Loenhout-Rooyackers, Verkorting van therapieduur bij patienten met longtuberculose van 9 naar 6 maanden verdedigbaar op grond van gepubliceerde gegevens Nederlands Tijdschrift voor Geneeskunde. ,vol. 140, pp. 2181- 2187 ,(1996)
K. Takayama, H.K. Schnoes, E.L. Armstrong, R.W. Boyle, Site of inhibitory action of isoniazid in the synthesis of mycolic acids in Mycobacterium tuberculosis. Journal of Lipid Research. ,vol. 16, pp. 308- 317 ,(1975) , 10.1016/S0022-2275(20)36719-5
C. L.A. Van Herwaarden, J. F. Broekmans, [The treatment of pulmonary tuberculosis: shorter and with more potency]. Nederlands Tijdschrift voor Geneeskunde. ,vol. 140, pp. 2160- 2163 ,(1996)